NO20054775L - Biaryl-substituerte triazoler som natriumkanalblokkere - Google Patents

Biaryl-substituerte triazoler som natriumkanalblokkere

Info

Publication number
NO20054775L
NO20054775L NO20054775A NO20054775A NO20054775L NO 20054775 L NO20054775 L NO 20054775L NO 20054775 A NO20054775 A NO 20054775A NO 20054775 A NO20054775 A NO 20054775A NO 20054775 L NO20054775 L NO 20054775L
Authority
NO
Norway
Prior art keywords
compounds
pain
alone
pharmaceutically acceptable
effective amount
Prior art date
Application number
NO20054775A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054775D0 (no
Inventor
Prasun K Chakravarty
Williams H Parsons
Michael H Fisher
Brenda Palucki
Min K Park
Bishan Zhou
James P Carey
Douglas E Frantz
Michael H Kress
Damian Weaver
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20054775D0 publication Critical patent/NO20054775D0/no
Publication of NO20054775L publication Critical patent/NO20054775L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20054775A 2003-03-18 2005-10-17 Biaryl-substituerte triazoler som natriumkanalblokkere NO20054775L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45595203P 2003-03-18 2003-03-18
PCT/US2004/007830 WO2004083190A1 (en) 2003-03-18 2004-03-12 Biaryl substituted triazoles as sodium channel blockers

Publications (2)

Publication Number Publication Date
NO20054775D0 NO20054775D0 (no) 2005-10-17
NO20054775L true NO20054775L (no) 2005-12-16

Family

ID=33030073

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054775A NO20054775L (no) 2003-03-18 2005-10-17 Biaryl-substituerte triazoler som natriumkanalblokkere

Country Status (34)

Country Link
US (2) US7326726B2 (de)
EP (1) EP1606269B1 (de)
JP (1) JP4482554B2 (de)
KR (1) KR100737721B1 (de)
CN (2) CN101289428A (de)
AR (1) AR044503A1 (de)
AT (1) ATE412639T1 (de)
AU (1) AU2004221885C1 (de)
BR (1) BRPI0408407A (de)
CA (1) CA2519252C (de)
CL (1) CL2004000551A1 (de)
CY (1) CY1108720T1 (de)
DE (1) DE602004017438D1 (de)
DK (1) DK1606269T3 (de)
EC (1) ECSP056018A (de)
EG (1) EG25994A (de)
ES (1) ES2314387T3 (de)
HR (1) HRP20050816A2 (de)
IS (1) IS8001A (de)
JO (1) JO2480B1 (de)
MA (1) MA27665A1 (de)
MX (1) MXPA05009847A (de)
MY (1) MY142651A (de)
NO (1) NO20054775L (de)
NZ (1) NZ542205A (de)
PE (1) PE20041066A1 (de)
PL (1) PL1606269T3 (de)
PT (1) PT1606269E (de)
RU (1) RU2356897C2 (de)
SI (1) SI1606269T1 (de)
TW (1) TWI337605B (de)
UA (1) UA81660C2 (de)
WO (2) WO2004083190A1 (de)
ZA (1) ZA200506906B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1587821T1 (sl) 2002-12-19 2009-02-28 Scripps Research Inst Sestavki in postopki za stabiliziranje transtiretina in zaviranje napaäśnega zvijanja transtiretina
AR044503A1 (es) * 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
AU2004289694B2 (en) 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers
CN101198598A (zh) 2004-05-20 2008-06-11 弗尔德里克斯制药股份有限公司 2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
DE602006015215D1 (de) 2005-10-10 2010-08-12 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
WO2008090117A1 (en) * 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
CN101679319B (zh) * 2007-02-08 2014-07-09 辛塔医药品有限公司 用于治疗增生性病症如癌症的三唑类化合物
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
RS56410B1 (sr) 2009-07-27 2018-01-31 Gilead Sciences Inc Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
JP5934787B2 (ja) 2011-05-10 2016-06-15 ギリアード サイエンシーズ， インコーポレイテッド イオンチャネルモジュレーターとしての縮合複素環式化合物
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (de) 2011-07-01 2018-04-28
RU2586330C2 (ru) 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
WO2013131018A1 (en) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
ES2694001T3 (es) 2013-03-15 2018-12-17 Bristol-Myers Squibb Company Moduladores de LXR
WO2016102967A1 (en) 2014-12-23 2016-06-30 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
CN112153968A (zh) 2017-10-05 2020-12-29 生物基因公司 制备α-羧酰胺吡咯烷衍生物的工艺
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
BR112020018403A2 (pt) * 2018-03-09 2020-12-22 Pi Industries Ltd. Compostos heterocíclicoscomo fungicidas
CN108794413A (zh) * 2018-06-25 2018-11-13 青岛科技大学 一种1,2,4-三氮唑-3-甲酰胺的合成方法
CN108863965A (zh) * 2018-06-25 2018-11-23 青岛科技大学 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875782A (en) * 1907-04-29 1908-01-07 Walter H Cook Fast-nut.
TW226993B (de) * 1992-05-29 1994-07-21 Kumiai Chemical Industry Co
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
IT1292091B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
DE60044395D1 (de) * 1999-03-26 2010-06-24 Euro Celtique Sa Arylsubstituierte pyrazole, imidazole, oxazole, thiazole und pyrrole, sowie deren verwendung
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
JP2004532234A (ja) * 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
ES2380319T3 (es) * 2002-07-09 2012-05-10 Bristol-Myers Squibb Company Derivados heterocíclicos sustituidos útiles como agentes antidiabéticos y anti-obesidad y procedimiento
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100470075B1 (ko) * 2002-11-21 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
AR044503A1 (es) * 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers

Also Published As

Publication number Publication date
AU2004221885C1 (en) 2010-09-23
KR100737721B1 (ko) 2007-07-11
UA81660C2 (ru) 2008-01-25
CN1788002A (zh) 2006-06-14
WO2004083190A1 (en) 2004-09-30
CA2519252C (en) 2008-11-18
MY142651A (en) 2010-12-15
TWI337605B (en) 2011-02-21
AR044503A1 (es) 2005-09-14
BRPI0408407A (pt) 2006-03-21
ES2314387T3 (es) 2009-03-16
US7572822B2 (en) 2009-08-11
JO2480B1 (en) 2009-01-20
WO2004083189A1 (en) 2004-09-30
CN101289428A (zh) 2008-10-22
CL2004000551A1 (es) 2005-01-21
ECSP056018A (es) 2006-01-27
AU2004221885B2 (en) 2010-04-22
NO20054775D0 (no) 2005-10-17
JP2006520782A (ja) 2006-09-14
MA27665A1 (fr) 2005-12-01
RU2005132168A (ru) 2006-04-27
EP1606269A1 (de) 2005-12-21
EG25994A (en) 2012-11-28
CA2519252A1 (en) 2004-09-30
CY1108720T1 (el) 2013-09-04
AU2004221885A1 (en) 2004-09-30
MXPA05009847A (es) 2005-12-05
ZA200506906B (en) 2007-02-28
US7326726B2 (en) 2008-02-05
ATE412639T1 (de) 2008-11-15
HRP20050816A2 (hr) 2006-04-30
SI1606269T1 (sl) 2009-02-28
PE20041066A1 (es) 2005-01-22
PL1606269T3 (pl) 2009-04-30
KR20050109583A (ko) 2005-11-21
NZ542205A (en) 2008-11-28
US20050119261A1 (en) 2005-06-02
DK1606269T3 (da) 2009-02-09
IS8001A (is) 2005-08-29
JP4482554B2 (ja) 2010-06-16
DE602004017438D1 (de) 2008-12-11
EP1606269B1 (de) 2008-10-29
US20080171777A1 (en) 2008-07-17
RU2356897C2 (ru) 2009-05-27
PT1606269E (pt) 2008-12-16
TW200505876A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
NO20054775L (no) Biaryl-substituerte triazoler som natriumkanalblokkere
NO20062676L (no) Substituerte triazoler som natriumkanalblokkere
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
WO2007112345A3 (en) Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
WO2007145922A3 (en) Benzazepinones as sodium channel blockers
WO2011027249A3 (en) Benzimidazole derivatives
WO2007075524A3 (en) Substituted piperidines as calcium channel blockers
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
WO2007112352A3 (en) Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
WO2007112357A3 (en) Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2009066041A3 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2010095768A8 (en) 4 -isopropylphenyl glucitol compounds as sglt1 inhibitors
HK1098758A1 (en) Polysulfated glycosides and salts thereof
EA201001094A1 (ru) Производные индазола
NO20001169L (no) 6,9-bro erythromycinderivater
MX2022009967A (es) Compuestos para el tratamiento de la infeccion por coronavirus.
BR0311136A (pt) composto ou um sal, enanciÈmero, diaestereÈmero ou éster hidrolisável in vivo ou mistura dos mesmos farmaceuticamente aceitável, composição, e, método para inibir a atividade de fator letal (lf) liberado de bactérias em um mamìfero
MXPA05010614A (es) Uso de derivados de 10-hidroxi-10,11-dihidrocarbamazepina para el tratamiento de trastornos afectivos.
WO2001014358A3 (en) Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
WO2010045582A3 (en) Compositions and methods for treating or preventing hypoxic or ischemic injury
JP2008531613A5 (de)
WO2007084394A3 (en) 2,5 diaza-bicyclo[2.2.1]heptane derivatives as calcium channel blockers
WO2023217800A3 (en) Synthesis of glycosylated hydroxytryptamine compounds and methods of their use
WO2023250141A3 (en) Methods of treating neurological ventilatory insufficiency
MX2023004435A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application